CN114773468B - Polypeptide specifically combined with PD-L1 and application thereof - Google Patents
Polypeptide specifically combined with PD-L1 and application thereof Download PDFInfo
- Publication number
- CN114773468B CN114773468B CN202210354704.3A CN202210354704A CN114773468B CN 114773468 B CN114773468 B CN 114773468B CN 202210354704 A CN202210354704 A CN 202210354704A CN 114773468 B CN114773468 B CN 114773468B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- tumor
- cells
- solution
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a polypeptide specifically combined with PD-L1 and application thereof. By examining the inhibition effect of the polypeptide on PD-1/PD-L1 protein combination in vitro, the anti-tumor effect in vitro and in vivo immune activation, the polypeptide is verified to be capable of blocking the PD-1/PD-L1 signal path and activating the immune response of T cells, and has the anti-tumor effect. The polypeptides of the invention may be prepared by solid phase synthesis methods. Compared with monoclonal antibodies and small molecular compounds, the polypeptide has the advantages of low manufacturing cost, high stability, low immunogenicity, strong organ or tumor penetrating capacity and the like.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a polypeptide for blocking interaction between a programmed death receptor PD-1 and a target PD-L1 thereof, which can be applied to preparation of anti-tumor therapeutic drugs.
Background
The immune checkpoint apoptosis receptor (Programmed cell death 1, PD-1) and its ligand (Programmed cell death ligand 1, PD-L1) bind under the influence of tumor microenvironment, and can inhibit the tumor killing function of T cells. Thus, blocking the interaction of PD-1 with PD-L1 is an effective means of anti-tumor immunosuppression and activating tumor immune responses. PD-L1 is highly expressed on the surfaces of various tumor cells, so that the PD-L1 can be used as an ideal immune anti-tumor target under the condition that the normal immune function of T cells is not affected. In recent years, the development of PD-1/PD-L1 inhibitors has become a research hotspot. The PD-1/PD-L1 inhibitors which are successfully developed and marketed at present are monoclonal antibodies, have high-strength specificity, and can be specifically combined with an immune checkpoint after administration, so that the immune checkpoint is prevented from being combined with a ligand thereof, and the immune suppression effect is avoided. In 2014, the first PD-1 inhibitor Pembrolizumab was approved by the FDA for use in advanced treatments of melanoma, non-small cell lung cancer, gastric cancer, liver cancer, and the like. At present, various PD-1/PD-L1 inhibitors are developed and marketed, and the PD-L1 monoclonal antibody inhibitors marketed at present for the advanced treatment of different cancers have better curative effects, but have the defects of high production cost, poor stability and the like because of the higher specificity of the PD-L1 monoclonal antibody inhibitors, and the polypeptide has the advantages of low production cost, high stability, low immunogenicity and high tissue permeability compared with a monoclonal antibody. Therefore, it is important to develop polypeptide inhibitors that avoid the above-mentioned drawbacks. In the invention, according to the characteristics of immune checkpoints, novel polypeptide inhibitors blocking PD-1/PD-L1 interaction are designed.
Disclosure of Invention
The invention provides a polypeptide inhibitor which can specifically bind to PD-L1 so as to block PD-1/PD-L1 interaction, regulate an immune system and have an anti-tumor effect.
In order to achieve the above purpose, the invention provides a polypeptide inhibitor capable of blocking PD-1/PD-L1 interaction, wherein the polypeptide has amphipathic alpha-helix property, and the amino acid sequence of the polypeptide is any one of the following sequences with 85% -99% of identity:
Peptide：H-G-D-W-F-K-A-Y-Y-D-K-V-A-E-G-OH(H-Gly-Asp-Trp-Phe-Lys-Ala-Tyr-Tyr-Asp-Lys-Val-Ala-Glu-Gly-OH)
the structural formula of the polypeptide is as follows:
further, the polypeptide is applied to block the interaction of PD-1/PD-L1 and overcome immune escape.
The application of the polypeptide in preparing a medicament for treating cancer:
the PD-L1 resisting polypeptide can be used for preparing antitumor drugs or antitumor treatment. Preferably, the tumor may be selected from breast cancer, non-small cell lung cancer, prostate cancer, renal cancer, melanoma, liver cancer, and the like. But are not limited to, antitumor drugs or antitumor therapies.
The technical scheme of the invention is as follows:
the polypeptide is synthesized by a solid-phase peptide mode, the resin of the first connected amino acid is subjected to deprotection after swelling, the next amino acid is condensed, and the like, so that the resin peptide is obtained for cutting, and the polypeptide can be obtained. The synthesized polypeptide has high binding affinity with PD-L1, and Homogeneous Time-resolved fluorescence (HTRF) technology shows that the polypeptide inhibitor can effectively block PD-1/PD-L1 interaction.
The polypeptide provided by the invention can inhibit the interaction of PD-1/PD-L1 in an in-vitro cell co-culture system. In a co-culture system of tumor cells MDA-MB-231 and Jurkat cells, the surface of the tumor cells MDA-MB-231 expresses PD-L1, and the interaction of the surface of the Jurkat cells expresses PD-1, PD-L1/PD-1 inhibits the secretion of cytokines such as IL-2 of the Jurkat cells. The polypeptide inhibitor has remarkable promoting effect on the secretion of IL-2 by Jurkat cells, and shows that the polypeptide can block PD-1/PD-L1 interaction and restore the immunity of Jurkat cells, thereby playing an attack on tumor cells MDA-MB-231.
The invention constructs a 4T1 tumor-bearing mouse model, induces the expression of tumor PD-L1 through murine IFN-gamma, and monitors the weight and tumor change of the mouse during the administration treatment period. After the administration is finished, the tumor of the mice treated by the polypeptide is obviously smaller than that of a BMS-202 positive control group, which indicates that the polypeptide has an anti-tumor effect. The concentration of IFN-gamma and IL-4 in the serum of the mice is obviously improved, and the immunohistochemical technique shows CD8 in the tumor tissue of the mice + The GZMB and IFN-gamma are obviously expressed, which proves that the polypeptide has the function of regulating the tumor immune system.
The invention has the advantages that:
1. the polypeptide provided by the invention can effectively block PD-1/PD-L1 interaction, has good performance in-vivo and in-vitro models, and has the specific effects of obviously improving the activity of T cells, eliminating the immunosuppressive effect, and preventing the immune escape of tumor cells so as to generate the tumor inhibiting effect.
2. Compared with monoclonal antibodies, the polypeptide provided by the invention has better tumor tissue penetrating power and can reduce immunogenicity.
3. The polypeptide of the invention has high biocompatibility and can not generate other influences on normal cells and organisms.
4. The polypeptide of the invention can be prepared by adopting a solid phase synthesis method, and is simple and feasible and low in cost.
Drawings
FIG. 1 is a graph showing the in vitro blocking effect of the polypeptide on PD-1/PD-L1 interactions using HTRF technology.
FIG. 2 shows experimental results of the polypeptide and positive control BMS-202 promoting IL-2 secretion by Jurkat cells over a range of concentrations when the Jurkat cells were co-cultured with MDA-MB-231 cells.
FIG. 3 is a graph showing the tumor inhibition effect of the polypeptide on 4T 1-tumor-bearing mice after two weeks of treatment.
FIG. 4 is a graph showing tumor growth in mice during treatment of 4T 1-tumor-bearing mice with the polypeptides.
FIG. 5 is a graph showing the change in body weight of mice during treatment of 4T 1-tumor-bearing mice with the polypeptides.
FIG. 6 is a graph showing the detection of the polypeptide by the Elisa method for promoting the expression of cytokine IL-4 in serum of 4T 1-tumor-bearing mice.
FIG. 7 is a graph showing the detection of the polypeptide by Elisa method for promoting the expression of cytokine IFN-gamma in serum of 4T 1-tumor-bearing mice
FIG. 8 shows the detection of GZMB, CD8 and IFN-gamma content in tumor tissue of 4T 1-tumor-bearing mice by IHC.
Detailed Description
The invention is further described by the following specific examples, which are given by way of illustration only and are not intended to limit the scope of the invention.
In vitro blocking of PD-1/PD-L1 interaction experiments with the Polypeptides described in example 1
1. Drug treatment
Before the experiment, the polypeptide to be detected and the positive control medicine (BMS-202) are respectively dissolved by a reagent Buffer and DMSO to prepare mother solution with the concentration of 100mM, and then the mother solution is respectively diluted into the solution to be detected of 10mM, 1000 mu M, 100 mu M, 10 mu M and 1 mu M by the reagent Buffer, and the solution to be detected is frozen at the temperature of minus 20 ℃. Tag1-PD-L1 (0.1 mg/mL, 1.845. Mu.M, 35. Mu.L) and Tag2-PD-1 (0.5 mg/Ml, 27.8. Mu.M, 25. Mu.L) protein working solutions in the HTRF kit were diluted with a reagent Buffer to final concentrations of 25nM and 250nM, respectively, and dispensed into sample tubes. Anti-Tag1-Eu energy donor in HTRF kit 3+ (25. Mu.L) and energy donor Anti-Tag2-XL665 (100. Mu.L) stock solutions were diluted 100-fold and 25-fold with Detection Buffer, respectively, dispensed into sample tubes, stored at-80℃in unison, and dispensed with reagents for use at the moment, avoiding repeated freeze thawing.
2. Experimental procedure
(1) A brand-new 96 shallow well plate is taken, a dosing group, a negative group, a positive group and a positive control group are preset, and three compound wells are selected and numbered.
(2) Tag2-PD-1, tagl-PD-L1, anti-Tagl-Eu were taken out from a-80℃refrigerator 3+ Anti-Tag2-XL665 working solution was thawed on ice.
(3) Adding 4. Mu.L of Tag1-PD-L1 working solution, 4. Mu.L of Tag2-PD-1 working solution and 2. Mu.L of polypeptide solution to the administration group by using a pipette; mu.L of Tag1-PD-L1 working solution, 4 mu.L of Tag2-PD-1 working solution and 2 mu.L of BMS-202 solution were added to the positive control group using a pipette; mu.L of Tag1-PD-L1 working solution, 4 mu.L of Tag2-PD-1 working solution and 2 mu.L of Diluent Buffer solution were added to the positive group by a pipette; mu.L of Tag1-PD-L1 working solution and 6. Mu.L of Diluent Buffer solution were added to the negative group using a pipette. Respectively blowing, mixing and incubating for 15 minutes.
(4) mu.L of Anti-Tag1-Eu was added to each well with a pipette 3+ mu.L of Anti-Tag2-XL665 stock solution, blowing and mixing uniformly, and then sealing the membrane and incubating for 2 hours in dark.
(5) After the incubation, the emission signal value of each well was determined using a BioTek multifunctional microplate reader, which stimulated at 320nm, emitted at 665nm, and emitted at 620nm, respectively.
(6) The transmitted signal ratio and the suppression ratio were calculated according to the following formulas, and the average value and Standard Deviation (SD) were repeatedly calculated.
Emission Ratio(ER)＝665nm Emission signal/620nm Emission signal
Rejection rate＝(ERpositive-ERsample)/(ERpositive-ERnegative)×100％
HTRF results (fig. 1) show that compound BMS-202 effectively blocks the interaction between PD-1 and PD-L1 by inducing dimerization of PD-L1, thereby inhibiting the formation of PD-1/PD-L1 complex. Although the polypeptides did not exhibit the same level of inhibitory activity as BMS-202, they had the ability to significantly block PD-1/PD-L1 interactions, with dose dependence. IC of the polypeptide 50 The value was 0.206. Mu.M. According to IC 50 The value indicates that the polypeptide has the capability of blocking tumor PD-1/PD-L1 binding, thereby activating CD8 + T cell secretionCytokines and inhibit tumor growth.
EXAMPLE 2 Co-culture of Jurkat cells with MDA-MB-231 cells, detection of IL-2 secretion from cell supernatants Using the Elisa method
1. Medium configuration: 20 μg of human IFN-gamma was dissolved in 1mL of ddH 2 In O, preparing a mother solution of 20 mug/mL, subpackaging the mother solution into a plurality of EP pipes, and freezing the EP pipes in an ultralow temperature refrigerator at-80 ℃. The DMEM complete medium is used for preparing the human IFN-gamma mother liquor into the DMEM complete medium containing 10ng/mL human IFN-gamma, and the DMEM complete medium is sub-packaged and frozen for storage. Similarly, phorbol 12-tetradecanoate 13-acetate (PMA) and Phytohemagglutinin (PHA) were prepared using RPMI-1640 complete medium to prepare RPMI-1640 complete medium containing 50ng/L PMA and 1. Mu.g/mL PHA, and frozen in aliquots.
2. Cell culture: breast cancer MDA-MB-231 cells were cultured in DMEM complete medium containing 10ng/mL of human IFN-gamma for 24 hours to induce MDA-MB-231 cells to highly express PD-L1, and Jurkat cells were cultured in RPMI-1640 complete medium containing 50ng/L PMA and 1. Mu.g/mL PHA for 24 hours to promote the differentiation of Jurkat cells.
3. Co-culturing cells: will be 1X 10 4 The individual MDA-MB-231 cells/well were added to a 96-well plate and incubated for 4 hours to allow the cells to adhere. The culture supernatant was then discarded and 4X 10 was added to each well 4 And Jurkat cells. The co-culture system was incubated at 37℃in an incubator for 48 hours.
IL-2 content detection:
(1) Collecting cell supernatant, centrifuging at 3000rpm in high-speed centrifuge for 20min, and collecting supernatant.
(2) Preparation of the washing buffer: diluting the concentrated washing buffer solution with distilled water for 30 times for later use, and heating in water bath until the concentrated washing buffer solution is completely dissolved if crystals are separated out.
(3) IL-2 standard curve solution preparation: IL-2 initial mother liquor concentration was 480pg/mL, 150. Mu.L of IL-2 initial mother liquor was added to the first centrifuge tube, and after being blown uniformly by a pipette, 150. Mu.L was sequentially transferred to the subsequent centrifuge tube to prepare IL-2 standard solution having concentrations of 320pg/mL, 160pg/mL, 80pg/mL, 40pg/mL, 20pg/mL and 10pg/mL, and IL-2 standard solution dilution buffer (0 pg/mL) was used as a blank well.
(4) Sample incubation and absorbance determination
Sample adding: 50 μl of the 6-concentration standard solution per well was added to the bottom of the wells of the ELISA plate. The sample groups are respectively 1 candidate polypeptide administration group (5 concentration gradients), 1 positive drug group (5 concentration gradients) and 1 normal control group, 10 mu L of sample to be tested is added to the bottom of an enzyme-labeled plate hole in each hole, the sample is diluted 5 times by sample diluent, 3 compound holes in each group are respectively provided, no sample and enzyme-labeled reagent are added, and the rest steps operate on the same blank hole. After the sample is added, the mixture is gently shaken to be uniformly mixed.
Sample incubation: after gently shaking and mixing, 96 microwell plates were sealed with a fresh sealing membrane and incubated at 37℃for 30 minutes.
Washing the plate: carefully tearing the sealing film, removing liquid by using a suction pipe, spin-drying, filling each hole with a washing buffer solution, standing for 30 seconds, discarding, washing the plate 5 times, and beating the ELISA plate.
Enzyme addition and incubation: 50 μl of enzyme-labeled reagent was added to each well, the 96 microwell plates were sealed with a fresh sealing membrane and incubated at 37deg.C for 30 minutes.
Washing the plate: carefully tearing the sealing film, removing liquid by using a suction pipe, spin-drying, filling each hole with a washing buffer solution, standing for 30 seconds, discarding, washing the plate 5 times, and beating the ELISA plate.
Color development: 50 mu L of the color reagent A and 50 mu L of the color reagent B are added into each hole, the mixture is gently shaken and mixed, and after the ELISA plate is wrapped by tin paper, the color is developed for 15 minutes at 37 ℃ in a dark place.
And (3) terminating: 50 mu L/Kong Zhongzhi liquid is added into each hole, the reaction is stopped, the mixture is gently shaken and uniformly mixed, and the color in the holes is changed from blue to yellow.
And (3) detection: the absorbance OD of each well was measured at 450nm using an enzyme-labeled instrument within 15 minutes of adding the stop solution.
(5) Data processing
And drawing a standard curve by taking the concentration of the standard substance as an abscissa and the OD value as an ordinate, and determining a linear regression equation. Substituting the OD value of the sample into a standard curve equation, calculating the concentration of the sample, and multiplying the concentration by the dilution factor to obtain the actual concentration of the sample.
To investigate the ability of the polypeptides at the cellular level to inhibit PD-1/PD-L1 interactions, the present invention co-cultures Jurkat cells with tumor cells MDA-MB-231 to mimic PD-1/PD-L1 interactions in vitro. The cytokine IL-2 is mainly released during Jurkat activation, so the secretion content of IL-2 can indicate that the polypeptide has the capacity of inhibiting PD-1/PD-L1 interaction, thereby presuming that the polypeptide has the capacity of blocking immune escape of tumor cells. As shown in fig. 2, the IL-2 levels of the polypeptide group were observed to be significantly higher than those of the control group over a range of concentrations, indicating that the polypeptides have the ability to inhibit PD-1/PD-L1 interactions. The polypeptide can restore IL-2 levels to 108.865pg/mL at a concentration of 200. Mu.M. In addition, positive control BMS-202 had the best effect in increasing IL-2 levels, demonstrating that the measurement of IL-2 secretion using the Elisa method was accurate.
EXAMPLE 3 in vivo anti-tumor Activity experiments Using the polypeptide as an example
The in vivo antitumor activity of the polypeptide was investigated by establishing a 4T 1-tumor-bearing mouse model, the method and results were as follows:
1. materials and grouping: 15 female balb/c mice, 6-8 weeks old, were ordered in the university of Jiangsu laboratory animal center. Mice were randomly divided into 3 groups of 5: polypeptide group (20 mg/kg), positive control BMS-202 (10 mg/kg), model group (physiological saline). 20mg of polypeptide is dissolved in 10mL of physiological saline to prepare 2mg/mL of polypeptide solution, and the polypeptide solution is packaged and frozen for storage. 1mL of 25mg/mL clear DMSO stock solution was added to 9mL of 20% SBE-beta-CD physiological saline solution, mixed well, 10mg of BMS-202 was dissolved in the solution to obtain 1mg/mL BMS-202 solution, and the solution was sub-packaged for frozen storage. 50 μg of murine IFN-gamma is dissolved in 0.5mL of ultrapure water, the volume is fixed to 66.67mL by using physiological saline, and the mixture is split-packed and frozen for standby.
2.4T1-construction of tumor-bearing mouse model: 4T1 cells were collected and suspended in PBS to prepare 1X 10 cells 7 Cell suspension/mL, breast cancer cells 4T1 were inoculated in the left underarm of mice, each 0.2mL.
3. Administration: until the tumor grows to a volume of about 100mm 3 0.2mL of 1000IU murine IFN-gamma is injected into the tumor,three consecutive days, used to induce tumor to highly express PD-L1. The next day, each intratumoral injection was administered at 0.2mL of drug every other day for 2 weeks. Tumor volume and mouse body weight were measured at the time of administration.
4. Tumor dissection: the following day after the end of the administration, mice were sacrificed by carbon dioxide asphyxiation, and then mice in the administration group and model group were dissected using a surgical instrument, and tumor tissues were completely peeled off and blood was taken from eyeballs.
As shown in fig. 3, the tumor volume of mice in the normal saline group was larger, while the tumor volume of mice in the polypeptide administration group was smaller. FIG. 4 shows that the volume of the saline group mice increases approximately 2.3 times after 18 days of treatment. In contrast, the polypeptide and positive control BMS-202 had a significant effect of inhibiting tumor growth. The tumor inhibition rate of the positive control BMS-202 group reaches 53.14%, and the tumor inhibition rate of the polypeptide group can reach 48.18%, which is slightly lower than 53.14% of that of the positive control BMS-202 group. Furthermore, the effect of the polypeptide on body weight in mice during treatment was negligible (fig. 5), indicating that the polypeptide was well tolerated and biocompatible.
The IL-4 and IFN-gamma content in the serum of mice was examined by the Elisa method, and the method and results were as follows:
1. blood obtained by eyeball extraction is kept stand at 4 ℃ overnight, and after delamination is carried out the next day, centrifugation is carried out at 5000rpm for 10min, and the supernatant is sucked for standby.
2. IL-4 and IFN-gamma levels were measured as described in example 2, elisa assay.
To further characterize the immune response, the secretion levels of IL-4 and IFN-gamma in mouse serum were compared as an important indicator of T cell activity. As shown in the attached figures 6 and 7, the IL-4 and IFN-gamma levels of the polypeptide group are significantly higher than those of the physiological saline group, and experimental results show that the polypeptide can effectively activate T cells, thereby increasing the anti-tumor capability.
EXAMPLE 4 investigation of GZMB, CD8 and IFN-gamma content in mouse tumor tissue by Immunohistochemical (IHC) method Using the polypeptide as an example
The method and the result are as follows:
1. drawing and fixing
The fresh tissue of the mouse is fully soaked in 4% paraformaldehyde fixing solution for 24 hours to denature and solidify the proteins of the tissue and cells so as to prevent autolysis or bacterial decomposition after cell death, thereby maintaining the original morphological structure of the cells.
2. Transparent dewatering
Generally, low-concentration to high-concentration alcohol is used as a dehydrating agent to gradually remove water from tissue blocks. And soaking the tissue block in a mixed solution of absolute ethyl alcohol and dimethylbenzene in a ratio of 1:1 for 20min, taking out, and then continuously soaking in another cylinder of pure dimethylbenzene for 10min.
3. Wax-impregnated embedding
Placing the transparent tissue block into melted paraffin, and placing into a paraffin dissolving box for heat preservation. Embedding after paraffin is completely immersed into the tissue block: firstly preparing a container, pouring melted paraffin, rapidly clamping a tissue block soaked with paraffin, and putting the tissue block into the container. Cooling and solidifying into blocks.
4. Slice and patch
The embedded wax block is fixed on a slicer and sliced, typically 5-8 μm thick. The cut sheet tends to be wrinkled, put into heated water to be ironed, then attached to a glass slide, and put into a 45 ℃ incubator to be dried.
5. Dewaxing
Soaking the slices in xylene for 3 times, 5 min/time, fresh xylene for the last time, absolute ethanol for 2 times, 5 min/time, fresh absolute ethanol for the last time, 95% ethanol for 1 time, 5min,90% ethanol for 1 time, 5min,75% ethanol for 1 time, 5min, ddH 2 O was washed 2 times on a shaker for 5 min/time.
6. Antigen retrieval
Soaking in antigen retrieval liquid (1X), heating at 100deg.C for 15min, naturally cooling to room temperature, ddH 2 O-washing for 2 times and 5 min/time, slicing, adding into 3% hydrogen peroxide water solution, and incubating at room temperature for 10min. Immunohistochemical circle drawing, goat serum blocking at 37 ℃ for 1h, pipetting off blocking solution, adding primary antibody, and incubating at 4 ℃ overnight (antibody recovery). The next day, after the first antibody incubation is finished, the temperature is put into room temperature, the temperature is raised back, the incubation is carried out for 30min at 37 ℃, the TBST buffer solution is washed for 3 times, 5 min/time,the secondary antibody was incubated at 37℃for 30min, washed 3 times with TBST buffer, 5 min/time. Streptavidin-biotin complex (SABC) was added, incubated at 37℃for 30min, and washed 3 times with PBS for 5 min/time. Staining with DAB developer, incubating at room temperature for 3-10min, ddH 2 O is washed away. Hematoxylin counterstain 20s, ddH 2 O washes off, acidic differentiation (2-5 s) (75% alcohol 99 mL+hydrochloric acid 1 mL), tap water washes for 10min.
7. Dewatering
Soaking the slices in 95% ethanol, dehydrating for 2min, and dehydrating fresh 95% ethanol for 2min; dehydrating 100% ethanol for 2min, and dehydrating fresh 100% ethanol for 2min; xylene soak for 2 times, 5 min/time, fresh xylene soak for 5min.
8. Neutral resin sealing piece
And 2-3 drops of tree glue solution are dropped at the center of the glass slide, then the cover glass is slowly put on, the tree glue solution is gently squeezed, the tree glue solution can be spread outwards to the whole lens, after the glass slide is ventilated and aired for a plurality of hours, the cotton balls are stuck with a transparent agent or turpentine is used for scrubbing the redundant gum at the edge of the lens. Then the mixture is placed in a ventilation place for airing, and the sealing piece can be stored at normal temperature.
As shown in FIG. 8, CD8 was infiltrated according to the tumor + The distribution of T cells shows that the treatment with the polypeptide significantly increases CD8 compared to BMS-202 + T cell infiltration degree. GZMB is an activated CD8 + In the result of immunohistochemistry, the cell factor secreted by the T cells has obviously increased GZMB content of the mouse tumor tissue of the polypeptide group compared with the physiological saline group. The polypeptide group enhanced IFN-gamma cytokine expression compared to the saline group. These results indicate that treatment with the polypeptide may result in a stronger immune response, which in turn has an inhibitory effect on tumor growth.
The above data were analyzed by GraphPad software Onway ANOVA test, with significance levels defined as: * p <0.05, < p <0.01, < p <0.001, < p <0.0001.
Sequence listing
<110> university of Jiangsu
<120> a polypeptide specifically binding to PD-L1 and use thereof
<141> 2022-04-06
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 14
<212> PRT
<213> Artificial Sequence
<400> 1
Gly Asp Trp Phe Lys Ala Tyr Tyr Asp Lys Val Ala Glu Gly
1 5 10
Claims (2)
1. The polypeptide specifically combined with PD-L1 is characterized by having amphipathic alpha-helix property, wherein the amino acid sequence of the polypeptide is shown as SEQ ID NO.1, and the structural formula of the polypeptide is as follows:
2. the use of a class of polypeptides that specifically bind to PD-L1 according to claim 1, for the preparation of an anti-tumor agent, wherein the tumor is breast cancer, non-small cell lung cancer, prostate cancer, renal cancer, melanoma, or liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210354704.3A CN114773468B (en) | 2022-04-06 | 2022-04-06 | Polypeptide specifically combined with PD-L1 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210354704.3A CN114773468B (en) | 2022-04-06 | 2022-04-06 | Polypeptide specifically combined with PD-L1 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114773468A CN114773468A (en) | 2022-07-22 |
| CN114773468B true CN114773468B (en) | 2023-10-10 |
Family
ID=82427711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210354704.3A Active CN114773468B (en) | 2022-04-06 | 2022-04-06 | Polypeptide specifically combined with PD-L1 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114773468B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948910A (en) * | 2014-02-24 | 2014-07-30 | 张家港市第一人民医院 | Use of immunomodulatory polypeptide ZL-1 in preparation of anti-tumor drugs |
| CN111205351A (en) * | 2020-01-19 | 2020-05-29 | 中国药科大学 | PD-1 targeted blocking peptide and application thereof |
| CN111533782A (en) * | 2020-05-08 | 2020-08-14 | 中国药科大学 | Active polypeptide of targeting immune checkpoint LAG-3 and application thereof |
-
2022
- 2022-04-06 CN CN202210354704.3A patent/CN114773468B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948910A (en) * | 2014-02-24 | 2014-07-30 | 张家港市第一人民医院 | Use of immunomodulatory polypeptide ZL-1 in preparation of anti-tumor drugs |
| CN111205351A (en) * | 2020-01-19 | 2020-05-29 | 中国药科大学 | PD-1 targeted blocking peptide and application thereof |
| CN111533782A (en) * | 2020-05-08 | 2020-08-14 | 中国药科大学 | Active polypeptide of targeting immune checkpoint LAG-3 and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114773468A (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sando et al. | Caveolin expression and localization in human keratinocytes suggest a role in lamellar granule biogenesis | |
| CN110734896A (en) | Wnt4/YWHAZ co-modified mesenchymal stem cell-derived exosome and preparation method and application thereof | |
| CN106701801B (en) | Detection marker and kit for B lymphoma and leukemia and application of detection marker and kit | |
| CN114773468B (en) | Polypeptide specifically combined with PD-L1 and application thereof | |
| CN114685612B (en) | Polypeptide inhibitor for blocking PD-1/PD-L1 binding and application thereof | |
| CN103969452B (en) | The classification diagnosis kit of BAY 43-9006 personalized treatment liver cancer | |
| CN114671926B (en) | Amphipathic alpha-helical polypeptide for inhibiting PD-L1 and application thereof | |
| CN109568583A (en) | Application of the RIPK3 as target spot in the drug of preparation prevention and treatment psoriasis | |
| CN105963699B (en) | Target spot and application of the FATS as melanoma immunization therapy | |
| Xu et al. | Tert-butyl hydroperoxide induces ferroptosis of bone mesenchymal stem cells by repressing the prominin2/BACH1/ROS axis | |
| CN107217060A (en) | KDM1A purposes | |
| CN110237257B (en) | Application of Ube3a ubiquitinated PP2A activator PTPA in treatment of Angel syndrome and autism | |
| CN116840486A (en) | Application of phosphorylation of Ser17 site of human PC4 protein in tumor cell proliferation regulation | |
| CN116953237A (en) | Human auxiliary transcription factor 4 ubiquitination site for tumor diagnosis and treatment and application thereof | |
| CN113912679A (en) | Polypeptide targeting androgen receptor, application thereof and medicament for preventing and treating prostatic cancer | |
| CN111214660B (en) | Application of PAX4 gene expression inhibitor in preparation of medicine for inhibiting fibrosis | |
| CN112824427B (en) | Short peptide for inhibiting glioma and application thereof | |
| CN109172557B (en) | Application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species | |
| Webb et al. | Hymenolepis diminuta: metacestode-induced reduction in the synthesis of the yolk protein, vitellogenin, in the fat body of Tenebrio molitor | |
| CN102552902A (en) | Preparation method of dendritic cell vaccine loaded with recombinant human gp96-Ki67 antigen peptide compound | |
| CN106755090B (en) | Method for screening drug for treating steatohepatitis by using apoptosis signal regulation kinase 1N-terminal dimerization as target spot | |
| CN111956786A (en) | Application of IGF-1 in preparation of medicine for preventing and/or treating liver tumor | |
| CN109517772A (en) | The building of Lactococcus lactis MG1363 a kind of and its application in treatment puerpera's cracked nipple | |
| CN107365373B (en) | Affinity peptide P527 targeting AKAP3 | |
| CN114381461B (en) | Application of promoting ATG5-ATG12 conjugation to enhance autophagy of cells by removing wild p53 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |